IP Verse

Glenmark Pharmaceuticals Europe Ltd opposition analysis

COMPANY ANALYSIS

Latest oppositions filed by Glenmark Pharmaceuticals Europe Ltd

Patent Number:
EP3578175
Title:
Rapid Dissolution Formulation Of A Calcium Receptor-Active Compound
Applicant:
AMGEN INC.
Opposition Date:
Aug 30, 2023
Patent Number:
EP2653873
Title:
Compositions And Uses For Treating Multiple Sclerosis
Applicant:
BIOGEN IDEC MA INC.
Opposition Date:
Apr 19, 2023
Patent Number:
EP2959894
Title:
S1P Receptor Modulators For Treating Multiple Sclerosis
Applicant:
NOVARTIS AG
Opposition Date:
Oct 12, 2022
Patent Number:
EP2817000
Title:
Oral Pharmaceutical Compositions Of Dabigatran Etexilate
Applicant:
ESTEVE PHARMACEUTICALS, S.A.
Opposition Date:
Apr 14, 2022
Patent Number:
EP2478907
Title:
Methods And Compositions For Treating Cancer
Applicant:
COUGAR BIOTECHNOLOGY, INC.
Opposition Date:
Jan 14, 2022
Patent Number:
EP2493466
Title:
Novel Antitumoral Use Of Cabazitaxel
Applicant:
AVENTIS PHARMA S.A.
Opposition Date:
Mar 10, 2021
Patent Number:
EP3395338
Title:
Rapid Dissolution Formulation Of Cinacalcet Hcl
Applicant:
AMGEN INC.
Opposition Date:
Jan 27, 2020
Patent Number:
EP3260117
Title:
Rapid Dissolution Formulation Of A Calcium Receptor-Active Compound
Applicant:
AMGEN INC.
Opposition Date:
Jan 16, 2020
Patent Number:
EP3395339
Title:
Rapid Dissolution Formulation Of A Cinacalcet Hcl
Applicant:
AMGEN INC.
Opposition Date:
Jan 16, 2020
Patent Number:
EP3395340
Title:
Rapid Dissolution Formulation Of Cinacalcet Hcl
Applicant:
AMGEN INC.
Opposition Date:
Jan 16, 2020

Competitors of Glenmark Pharmaceuticals Europe Ltd

AMGEN INC.

AMGEN, INC

EURO-CELTIQUE S.A.

Want to track Glenmark Pharmaceuticals Europe Ltd?

Feel free to send us a message here and we will get back to you